ArticleBMC public health2025
Knowledge and attitudes towards vitiligo in egyptian and palestinian communities: a cross-sectional study.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVitiligo is an acquired dermatological condition characterized by localized skin depigmentation. It affects 0.5% to 2% of the population, impacting individuals across various ages, races, and genders. The psychosocial effects of Vitiligo can significantly influence quality of life, particularly in people with darker skin tones, where the contrast of lesions is more pronounced.
objectivesThis study evaluated public knowledge, attitudes, and misconceptions regarding Vitiligo in Egypt and Palestine, focusing on specific demographic Variations and the potential need for improved community engagement and education.
methodA multicenter cross-sectional study was conducted involving 1,045 participants from Egypt and 450 participants from the West Bank. An online self-administered questionnaire was developed using Google Forms. The eligibility criteria for participation included Egyptian and Palestinian citizens residing in the West Bank. Individuals under 18 years or outside the designated study settings were excluded from participation. This study was conducted from April 2024 to August 2024.
resultsThe analysis indicated that 62.8% of participants demonstrated adequate knowledge of Vitiligo; however, only 87.6% exhibited favorable attitudes toward the condition. The study revealed significant variations in knowledge and attitudes based on gender, occupation, previous health professional experience, and social status. Economic level and geographic location. Educational level was found to have a considerable impact on attitudes. Multiple linear regression analysis identified several significant predictors of. Knowledge and attitude scores included male gender, age categories of 18 to 25 and over 50, marital status, occupation in a health profession, personal experience with Vitiligo, prior awareness of the condition, and the attitude score itself. This explained 30.2% of the variance in knowledge scores and 28.1% in attitude ratings.fig.
conclusionThis study provides valuable insights into public awareness and perceptions of Vitiligo in Egypt and Palestine. A significant proportion of the participants demonstrated adequate awareness of the condition; however, favorable opinions appeared less prevalent. Notable discrepancies were observed among the various demographic characteristics, highlighting the need for targeted initiatives, such as media campaigns and school-based education, aimed at addressing information gaps and improving public perception.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.